Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study

Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study. Blanchard, P.; Pugh, T. J.; Swanson, D. A.; Mahmood, U.; Chen, H. C.; Wang, X.; Graber, W. J.; Kudchadker, R. J.; Bruno, T.; Feeley, T.; Frank, S. J.. Brachytherapy. 2018; 265-276: p.265-276. doi:10.1016/j.brachy.2017.11.007
Article